Third drug signed off for early access in France
This article was originally published in SRA
Johnson & Johnson/MSD's Remicade (infliximab) is to be made available to French patients for the unapproved indication of Takayasu's arteritis refractory to conventional drugs, under a temporary use recommendation (RTU)1. Remicade is the third drug to be granted an RTU, a relatively new early-access mechanism, in France.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.